Teva CEO exits in ongoing crisis of confidence at drugmaker
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Mizuho Reiterates Neutral Rating for Teva (TEVA) Following CEO Departure
February 7, 2017 5:38 AM ESTMizuho Securities analyst Irina Koffler maintains Neutral rating and $40 price target on Teva Pharmaceuticals (NYSE: TEVA) suggesting management change may not impact stock performance. Chairman of the Board, Dr. Yitzhak Peterburg, will begin serving as President and Interim CEO immediately.
Koffler comments, Teva... More
